Diroximel fumarate - Alkermes/Biogen

Drug Profile

Diroximel fumarate - Alkermes/Biogen

Alternative Names: ALKS-8700; BIIB-098

Latest Information Update: 11 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkermes plc
  • Class Anti-inflammatories; Fumarates; Pyrrolidines; Small molecules
  • Mechanism of Action Immunomodulators; NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Multiple sclerosis

Most Recent Events

  • 06 Jun 2018 Alkermes plc announces intention to submit 505(b) NDA to the US FDA for Multiple sclerosis in the fourth quarter of 018 (94647)
  • 21 Apr 2018 Pharmacokinetic and safety data from the phase I trial in Multiple sclerosis presented at the 70th Annual Meeting of the American Academy of Neurology (AAN-2018)
  • 30 Jan 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top